Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Eli Lilly said it would invest $3 billion to expand a recently ... a study that claimed that its Zepbound obesity drug is ...